--- title: "U.S. stock night trading volatility: Gossamer Bio rose 5.19% in after-hours trading, boosted by dual positive factors of debt restructuring and successful trials enhancing market confidence" type: "News" locale: "en" url: "https://longbridge.com/en/news/286855002.md" description: "Gossamer Bio rose 5.19% in after-hours trading; BeiGene rose 1.22% in after-hours trading, with a transaction volume of USD 173,900; Intellia Therapeutics rose 0.08% in after-hours trading, with a transaction volume of USD 101,600; Natera rose 0.34% in after-hours trading, with a transaction volume of USD 98,500" datetime: "2026-05-19T04:51:33.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/286855002.md) - [en](https://longbridge.com/en/news/286855002.md) - [zh-HK](https://longbridge.com/zh-HK/news/286855002.md) --- # U.S. stock night trading volatility: Gossamer Bio rose 5.19% in after-hours trading, boosted by dual positive factors of debt restructuring and successful trials enhancing market confidence **U.S. Stock Night Market Movements** Gossamer Bio rose 5.19% in the night market. Based on recent key news: 1. On May 18, Gossamer Bio announced the launch of an exchange offer and consent solicitation aimed at eliminating over $120 million in debt and gaining support from existing bondholders. This news boosted market confidence and drove the stock price up. 2. On May 18, Gossamer Bio released its first-quarter financial report, showing a net income of -$46.664 million, an operating income of -$44.866 million, and operating expenses of $61.821 million. Despite the report showing losses, the market expressed optimism about its future cash flow and operational capabilities, leading to an increase in stock price. 3. On May 18, Gossamer Bio's Phase III PROSERA trial results showed that seralutinib achieved clinically significant improvements in the treatment of PAH, supporting its NDA submission goals. This positive trial result further enhanced investor confidence, driving the stock price up. The biotechnology industry has recently performed strongly, with significant capital inflows. **Stocks with High Trading Volume in the Industry** BeiGene rose 1.22% in the night market. Based on recent key news: 1. On May 15, BeiGene announced active discussions with the FDA to determine the next steps for clinical trials and plans to unblind accumulated clinical data to assess efficacy and safety. This news strengthened market confidence in its drug development progress, driving the stock price up. Source: Pharmaceutical Executive Daily 2. On May 15, BeiGene's founder and CEO John Oyler stated that the company has evolved from a disruptive idea into a globally operating oncology drug company, with three commercially approved drugs and over 50 clinical projects in its pipeline. This news further solidified investor confidence in the company's long-term growth potential. Source: Pharmaceutical Executive Daily 3. On May 15, BeiGene's drug Beqalzi received FDA approval for the treatment of mantle cell lymphoma, a milestone event that enhanced the company's position in the oncology treatment field and stimulated the stock price increase. Source: Pharmaceutical Executive Daily The competition in the oncology drug market is intensifying, and the regulatory environment is changing. Intellia Therapeutics rose 0.08%. There has been no significant news recently; trading is active, and capital flows are evident. Considering the sector and industry trends, this stock shows significant volatility, and specific reasons need further observation. no\_news Natera rose 0.34% in the night market. Based on recent key news: 1. On May 15, the FDA approved Natera's Signatera CDx as a companion diagnostic device for adjuvant treatment in patients with muscle-invasive bladder cancer This approval is based on the results of the IMvigor011 Phase III trial, which significantly extended patients' disease-free survival and overall survival, driving up Natera's stock price. 2. On May 15, Genentech, a subsidiary of Roche, announced that Tecentriq received FDA approval for adjuvant treatment of bladder cancer, and the approval of Signatera CDx as a companion diagnostic further enhanced market confidence in Natera. 3. On May 15, Natera stated that its Signatera CDx showed significant survival improvements in trials, particularly among high-risk patients who tested positive for MRD, which raised investors' expectations for the company's products. Recent policy support and significant capital inflow in the biotechnology industry ### Related Stocks - [GOSS.US](https://longbridge.com/en/quote/GOSS.US.md) - [ONC.US](https://longbridge.com/en/quote/ONC.US.md) - [NTLA.US](https://longbridge.com/en/quote/NTLA.US.md) - [NTRA.US](https://longbridge.com/en/quote/NTRA.US.md) ## Related News & Research - [Gossamer Bio Enters Noteholder Support Pact to Advance Convertible Notes Exchange](https://longbridge.com/en/news/286761105.md) - [15:36 ETGossamer Bio, Inc. (GOSS) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit](https://longbridge.com/en/news/286307280.md) - [Gossamer Bio to Announce First Quarter 2026 Financial Results and Host Conference Call and Webcast on May 18, 2026 | GOSS Stock News](https://longbridge.com/en/news/286553329.md) - [Gossamer Bio Restructures Debt and Advances Seralutinib Program](https://longbridge.com/en/news/286763165.md) - [11:05 ETGOSS INVESTOR NOTICE: Faruqi & Faruqi, LLP Reminds Gossamer Bio (GOSS) Investors of Securities Class Action Deadline on June 1, 2026](https://longbridge.com/en/news/286436942.md)